Cargando…

Time for Precision: A World Without Susceptibility Breakpoints

Interpretive criteria for in vitro susceptibility testing criteria, “susceptibility breakpoints,” underpin the evaluation and selection of antimicrobial regimens. However, despite their strengths, susceptibility breakpoints are a relatively blunt instrument employed to address an extremely complex q...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bader, Justin C, Lakota, Elizabeth A, Andes, David R, Rubino, Christopher M, Ambrose, Paul G, Bhavnani, Sujata M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297858/ https://www.ncbi.nlm.nih.gov/pubmed/30581880 http://dx.doi.org/10.1093/ofid/ofy282

Ejemplares similares

1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States
por: Flamm, Robert K, et al.
Publicado: (2019)

Traditional PK-PD Indices for Efficacy – Can We Do Better?
por: Lakota, Elizabeth A, et al.
Publicado: (2017)

1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates
por: Pfaller, Michael A, et al.
Publicado: (2019)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters
por: Lakota, Elizabeth A., et al.
Publicado: (2017)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)
por: Pogue, Jason M, et al.
Publicado: (2019)

2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients
por: Ambrose, Paul G, et al.
Publicado: (2020)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
por: Bhavnani, Sujata M., et al.
Publicado: (2023)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
por: Bader, Justin C, et al.
Publicado: (2017)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
por: Lakota, Elizabeth A, et al.
Publicado: (2019)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

228. Epidemiology and Susceptibility Profiles of ST131-O25b Escherichia coli Detected Among Cephalosporin and/or Carbapenem-Resistant Isolates Collected in United States Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive
por: Safir, M. Courtney, et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
por: Ganesan, Harish, et al.
Publicado: (2022)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints
por: Astvad, Karen Marie Thyssen, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Precise detection of rearrangement breakpoints in mammalian chromosomes
por: Lemaitre, Claire, et al.
Publicado: (2008)

1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)
por: VanScoy, Brian D, et al.
Publicado: (2018)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

Life in a World without Microbes
por: Gilbert, Jack A., et al.
Publicado: (2014)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development
por: Bhavnani, Sujata M, et al.
Publicado: (2020)

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods
por: Zhang, Li, et al.
Publicado: (2019)

The pyrazinamide susceptibility breakpoint above which combination therapy fails
por: Gumbo, Tawanda, et al.
Publicado: (2014)

Precise breakpoint detection in a patient with 9p– syndrome
por: Ng, Jeffrey, et al.
Publicado: (2020)

Susceptibility breakpoint for Danofloxacin against swine Escherichia coli
por: Yang, Yuqi, et al.
Publicado: (2019)

Impact of revised breakpoints on the categorization of susceptibility of Enterobacterales to temocillin
por: Farfour, Eric, et al.
Publicado: (2023)

1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study
por: Onufrak, Nikolas J, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies
por: Trang, Michael, et al.
Publicado: (2019)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide
por: Ganesan, Harish, et al.
Publicado: (2021)

A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
por: Regier, Dean A., et al.
Publicado: (2022)

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?
por: Tamma, Pranita D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6hpaep5tr540v9sm707c5dcp7e